Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study

Vladimir LazarevicDepartment of Hematology, Lund University, Lund, SwedenCorrespondence[email protected]

Mats RembergerKarolinska Institutet and Division of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden

Hans HägglundHematology Center, Karolinska University Hospital, Stockholm, Sweden

Gunnar JuliussonDepartment of Hematology, Lund University, Lund, Sweden;Skåne University Hospital, Lund, Sweden

Hamdy OmarHematology Center, Karolinska University Hospital, Stockholm, Sweden

Helene HalböökDepartment of Hematology, Uppsala University Hospital, Uppsala, Sweden

Eva KimbyHematology Center, Karolinska University Hospital, Stockholm, Sweden

Claes MalmDepartment of Hematology, University Hospital of Linköping, Linköping, Sweden

Anders WahlinDepartment of Oncology and Hematology, Umeå University Hospital, Umeå, Sweden

Jan-Erik JohanssonDepartment of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden

show all

References

Storb RF, Champlin R, Riddell SR, . Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program 2001:375–391.
PubMedGoogle Scholar
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
Web of Science ®Google Scholar
Gooley TA, Leisenring W, Crowley J, . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695–706.
PubMed Web of Science ®Google Scholar
Fine J, Gray R. Proportional hazard model for the subdistribution of competing risks. J Am Stat Assoc 1999;94:496–509.
Web of Science ®Google Scholar
Rezvani AR, Norasetthada L, Gooley T, . Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicenter experience. Br J Haematol 2008;143:395–403.
PubMed Web of Science ®Google Scholar
van Kampen RJ, Canals C, Schouten HC, . Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011;29:1342–1348.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date